![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » DRUG MAJORS INVEST IN BRAZILIAN IT SYSTEMS
DRUG MAJORS INVEST IN BRAZILIAN IT SYSTEMS
September 23, 2005
As a testimony to Brazil's growing importance as a regional base for drug multinationals, investment in information technology appears to be growing. In recent months, major companies including Bristol-Myers Squibb (BMS) have initiated IT-based programmes in the country.
Switzerland's Roche has, according to the local media, also invested US$21mn in a new finance and human resources facility, while BMS's activity has involoved an outsourcing project. Several companies have cited Brazil's abundance of skilled labour and low operational costs as reasons for investing in local IT. Activity is generally centred on the vast conurbation of São Paulo city, which is attempting to re-brand itself as South America's leading services hub.
Nevertheless, the size of the local market is also undoubtedly an important factor in foreign company investment decisions. As well as offering an expanding clinical trials base, Brazil's drug sales are expected to reach US$13.6bn in 2009.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct